Foghorn Therapeutics(FHTX)
CAMBRIDGE, MA
Biotechnology4 H-1B visas (FY2023)Focus: Cancer Drug Discovery, Protein Degradation
Foghorn Therapeutics is a life sciences company focused on Cancer Drug Discovery, Protein Degradation.
Oncology
Funding Stage
PUBLIC
Open Jobs
1
Pipeline & Clinical Trials
FHD-286
Metastatic Uveal MelanomaClinical Trials (1)
NCT04879017FHD-286 in Subjects With Metastatic Uveal Melanoma
Phase 1Decitabine
Acute Myeloid LeukemiaClinical Trials (1)
NCT07283094FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
Phase 1FHD-609
Advanced Synovial SarcomaClinical Trials (1)
NCT04965753FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors
Phase 1Phase 1
Clinical Trials (1)
NCT04891757FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies
Phase 1Open Jobs (1)
Interview Prep Quick Facts
Portfolio: 4 clinical trials
H-1B (2023): 4 approvals
SEC Filings: 2 available
Open Roles: 1 active job
Financials (FY2025)
Revenue
$23M34%
R&D Spend
$95M(418%)14%
Net Income
-$87MCash
$55MHiring Trend
Stable
1
Open Roles
+1
Added
-0
Filled/Removed
Based on last 4 crawl cycles
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
4
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub